Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $73.00

Posted by Brian Himes on Oct 22nd, 2026

Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its price objective raised by HC Wainwright from $65.00 to $73.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Enliven Therapeutics’ Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.74) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.06) EPS.

Several other brokerages have also recently issued reports on ELVN. Guggenheim reissued a “buy” rating on shares of Enliven Therapeutics in a research note on Thursday, October 8th. The Goldman Sachs Group increased their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. began coverage on Enliven Therapeutics in a report on Thursday, October 1st. They issued an “overweight” rating and a $75.00 target price on the stock. Barclays started coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target for the company. Finally, Stifel Nicolaus upped their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $75.44.

View Our Latest Report on ELVN

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $41.82 on Monday. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32. The firm has a 50 day moving average price of $50.93 and a 200 day moving average price of $48.00.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts expect that Enliven Therapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. The trade was a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director owned 13,000 shares of the company’s stock, valued at approximately $606,710. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 189,849 shares of company stock worth $11,054,870. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

Large investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in Enliven Therapeutics by 276.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock worth $52,898,000 after buying an additional 847,399 shares during the period. First Light Asset Management LLC lifted its holdings in Enliven Therapeutics by 574.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after buying an additional 1,158,883 shares in the last quarter. Tidal Investments LLC lifted its holdings in Enliven Therapeutics by 27.7% in the 2nd quarter. Tidal Investments LLC now owns 60,694 shares of the company’s stock worth $3,080,000 after buying an additional 13,179 shares in the last quarter. WINTON GROUP Ltd purchased a new position in Enliven Therapeutics in the 2nd quarter valued at about $228,000. Finally, Engineers Gate Manager LP purchased a new position in Enliven Therapeutics in the 2nd quarter valued at about $1,479,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Trending Headlines about Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

Positive Sentiment: HC Wainwright reiterated a Buy rating and $73 price target, substantially above the recent trading level. The firm forecasts a 2026 loss of $1.74 per share, slightly better than the $1.81 consensus estimate, providing a positive valuation signal if the company meets expectations.
Positive Sentiment: HC Wainwright expects quarterly losses of $0.41 per share in Q3 2026 and $0.46 in Q4 2026, followed by losses of $0.48, $0.50, $0.52 and $0.55 per share in the first four quarters of 2027. While still unprofitable, the estimates give investors a forward outlook and support the analyst’s bullish target.
Neutral Sentiment: The firm projects a full-year 2027 loss of $2.06 per share, underscoring that Enliven remains a development-stage biotechnology company dependent on future clinical and commercial progress rather than current earnings.
Negative Sentiment: CFO Benjamin Hohl sold 6,018 shares for approximately $231,573, reducing his direct ownership by 13.67%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which makes it less concerning than an unexpected discretionary sale, but it may still weigh on sentiment. SEC insider transaction filing

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.